Replies to post #3567 on Long Term Investment, Biotech & High Yield Dividen

[knulp]

Dear _BBB_ DVAX will surge dramatically...HEPLISAV is the key, GSK will buy right when and if or before FDA will remove the clinical hold. Heplisav will have easier steps in Europe, vaccine for hepatitis b is needed worlwide, even if FDA stops the development, DVAX will licence outside of USA.

I'm betting on 30 millions upfront payment plus royalties: no reason DVAX is trading at less than its end 2009 year cash position (estimated in 50 millions, excluding other probable milestones payments and funds committments by partners), if cash surge at 90/100 then using the same actual insane multiple will trade at 1.25, but we know that with a marketable product and sale'products revenues this co.may reach at least 7/10$.

O/s is only 40 millions, but float is only 25...BVF and others funds control together the 35/40% of the company.

I would appreciate if you post the post or some parts more interesting for you on SHEFF, because I cannot.

Best regards